1. Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy
   Chuanli Ren et al, 2016, International Journal of Cancer CrossRef
2. Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer
   Daniel C. Danila et al, 2016, Manual of Molecular and Clinical Laboratory Immunology CrossRef
3. uPA/PAI-1 et EPClin® : comparaison de leur impact sur la prise en charge des cancers du sein de pronostic intermédiaire
   P. Maniez et al, 2022, Gynécologie Obstétrique Fertilité & Sénologie  CrossRef
4. The Role of Circulating Tumor Cells in Breast Cancer and Implications for Radiation Treatment Decisions
   Chelain R. Goodman et al, 2021, International Journal of Radiation Oncology*Biology*Physics CrossRef
5. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer
   Chelain R. Goodman et al, 2018, JAMA Oncology CrossRef
6. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients
   Kjersti Tjensvoll et al, 2019, BMC Cancer CrossRef
7. Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score
   Puneet Singh et al, 2020, Breast Cancer Research and Treatment CrossRef
8. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients
   Fausto Petrelli et al, 2015, Breast Cancer Research and Treatment CrossRef
9. Real-world utilization of the 21-gene assay in taiwanese female patients with early-stage breast cancer: Experience from a single institute
   Shang-Hung Chen et al, 2022, Journal of Cancer Research and Practice CrossRef
10. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
    E.J. Blok et al, 2018, Cancer Treatment Reviews CrossRef
11. Liquid biopsy as a cancer biomarker-potential, and challenges
    Daniel C. Danila, 2022, Cancer Biomarkers CrossRef
12. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing
    Bradley M. Turner et al, 2023, Cancers CrossRef
13. Circulating Tumour Cells in Primary Disease: The Seed for Metastasis
    Noam Falbel Pondé et al, 2017, Liquid Biopsies in Solid Tumors CrossRef
14. Expression and clinical value of PD‐L1 which is regulated by BRD4 in tongue squamous cell carcinoma
    Lu Zhao et al, 2020, Journal of Cellular Biochemistry CrossRef
15. Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach
    Bradley M. Turner et al, 2021, Human Pathology Reports CrossRef
16. Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score
    Andreas D. Hartkopf et al, 2016, Breast Cancer Research and Treatment CrossRef
17. Association between 21-gene-assay and detection of disseminated tumor cells in patients with early breast cancer: results from the IRMA trial
    Léa L. Volmer et al, 2023, Breast Cancer Research and Treatment CrossRef